Medicaid coverage practices for approved gene and cell therapies: Existing barriers and proposed policy solutions

The current Medicaid system is ill equipped to handle the anticipated approvals of new gene and cell therapy products. These advanced therapies tend to be single-dose, potentially durable options for a variety of indications spanning oncology, rare disease, and more. The up-front cost of these thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Allen, Jeremy, Berry, Diane, Cook, Francesca, Hume, Ashley, Rouce, Rayne, Srirangam, Anirudh, Wellman, Jennifer, McCombs, Caitlin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242491/
https://www.ncbi.nlm.nih.gov/pubmed/37287748
http://dx.doi.org/10.1016/j.omtm.2023.05.015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242491/
https://www.ncbi.nlm.nih.gov/pubmed/37287748
http://dx.doi.org/10.1016/j.omtm.2023.05.015

Ejemplares similares